Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans (Q46211189)

20 December 2017

title

Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans (English)

1 reference

20 December 2017

1 reference

11

Mauricio Maia

1 reference

20 December 2017

Yan Xin

1

1 reference

20 December 2017

Shuang Bai

2

1 reference

20 December 2017

Lisa A Damico-Beyer

3

1 reference

20 December 2017

Denise Jin

4

1 reference

20 December 2017

Wei-Ching Liang

5

1 reference

20 December 2017

Yan Wu

6

1 reference

20 December 2017

Frank-Peter Theil

7

1 reference

20 December 2017

Amita Joshi

8

1 reference

20 December 2017

Yanmei Lu

9

1 reference

20 December 2017

John Lowe

10

1 reference

20 December 2017

Rainer K Brachmann

12

1 reference

20 December 2017

Hong Xiang

13

1 reference

20 December 2017

publication date

16 June 2012

1 reference

20 December 2017

published in

Pharmaceutical Research

1 reference

20 December 2017

volume

29

1 reference

20 December 2017

issue

9

1 reference

20 December 2017

page(s)

2512-2521

1 reference

20 December 2017

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Target-mediated drug disposition and dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Interspecies scaling of therapeutic monoclonal antibodies: initial look

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Neuropilins in neoplasms: expression, regulation, and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Neuropilin is a receptor for the axonal chemorepellent Semaphorin III

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Identification of two novel alternatively spliced Neuropilin-1 isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0781-X

A requirement for neuropilin-1 in embryonic vessel formation.

21 January 2018

1 reference

12 December 2020

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

12 December 2020

From the discovery of neuropilin to the determination of its adhesion sites

1 reference

12 December 2020

Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1

1 reference

12 December 2020

10.1007/S11095-012-0781-X

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017